KR20220146561A - 리포산 콜린 에스테르 염의 제약 조성물 및 이를 이용한 치료 방법 - Google Patents

리포산 콜린 에스테르 염의 제약 조성물 및 이를 이용한 치료 방법 Download PDF

Info

Publication number
KR20220146561A
KR20220146561A KR1020227033130A KR20227033130A KR20220146561A KR 20220146561 A KR20220146561 A KR 20220146561A KR 1020227033130 A KR1020227033130 A KR 1020227033130A KR 20227033130 A KR20227033130 A KR 20227033130A KR 20220146561 A KR20220146561 A KR 20220146561A
Authority
KR
South Korea
Prior art keywords
lipoic acid
lace
tosylate
pharmaceutical composition
choline ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227033130A
Other languages
English (en)
Korean (ko)
Inventor
크리스토프 부허
디트마 플루바하
제레미아 더글라스 포우치
말레이 고쉬
조안 프란즈 클루게
자이싱 리
케일 리 맥앨리스터
릴라드하르 멀리드하르 웨이콜
옌스 조렌 보르트만
팅잉 주
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20220146561A publication Critical patent/KR20220146561A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020227033130A 2020-03-13 2021-03-12 리포산 콜린 에스테르 염의 제약 조성물 및 이를 이용한 치료 방법 Ceased KR20220146561A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020079271 2020-03-13
CNPCT/CN2020/079271 2020-03-13
US202063013836P 2020-04-22 2020-04-22
US63/013,836 2020-04-22
PCT/IB2021/052092 WO2021181361A1 (en) 2020-03-13 2021-03-12 Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same

Publications (1)

Publication Number Publication Date
KR20220146561A true KR20220146561A (ko) 2022-11-01

Family

ID=75108681

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227033130A Ceased KR20220146561A (ko) 2020-03-13 2021-03-12 리포산 콜린 에스테르 염의 제약 조성물 및 이를 이용한 치료 방법

Country Status (18)

Country Link
US (2) US11135239B1 (cg-RX-API-DMAC10.html)
EP (1) EP4118079A1 (cg-RX-API-DMAC10.html)
JP (2) JP7041298B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220146561A (cg-RX-API-DMAC10.html)
CN (2) CN113387923A (cg-RX-API-DMAC10.html)
AU (1) AU2021235563A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018043A2 (cg-RX-API-DMAC10.html)
CA (1) CA3175077A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022012653A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220449A (cg-RX-API-DMAC10.html)
DO (1) DOP2022000179A (cg-RX-API-DMAC10.html)
EC (1) ECSP22069611A (cg-RX-API-DMAC10.html)
IL (1) IL295378A (cg-RX-API-DMAC10.html)
JO (1) JOP20220211A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022011206A (cg-RX-API-DMAC10.html)
PE (1) PE20230242A1 (cg-RX-API-DMAC10.html)
TW (1) TWI768760B (cg-RX-API-DMAC10.html)
WO (1) WO2021181361A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026518762A (ja) 2023-05-24 2026-06-09 温州医科大学附属眼視光医院 効果的に近視を先送りにし治療する医薬組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5520920A (en) 1978-07-31 1980-02-14 Honda Motor Co Ltd Device for absorbing twisting vibration of drive system
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
AR050902A1 (es) * 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
DE102006062599B4 (de) 2006-12-29 2018-03-08 Endress + Hauser Gmbh + Co. Kg Opto-elektronische Vorrichtung zur Übertragung eines elektrischen Signals und deren Verwendung
WO2009038656A1 (en) 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
EP3069612A3 (en) 2009-06-15 2016-10-19 Encore Health, LLC Dithiol compounds, derivatives, and uses therefor
ES2579173T3 (es) 2009-06-15 2016-08-05 Encore Health, Llc Ésteres de colina para tratar presbicia y cataratas
EP3113613A4 (en) * 2014-03-03 2019-03-13 Encore Vision, Inc. LIPOIC ACID CHOLINESTER COMPOSITIONS AND METHOD OF USE THEREOF
WO2016126662A1 (en) 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
WO2016164534A1 (en) 2015-04-09 2016-10-13 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
WO2016176089A1 (en) 2015-04-29 2016-11-03 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
ES2904580T3 (es) * 2015-09-24 2022-04-05 Novartis Ag Composiciones de éster de colina del ácido lipoico y métodos para generar formulaciones oftálmicas biocompatibles.
JOP20190057A1 (ar) * 2016-09-23 2019-03-24 Encore Vision Inc تركيبات استر كولين حمض الليبويك وطرق تثبيتها إلى منتجات عقار ذات صلة دوائية
CN106967044B (zh) * 2017-05-12 2019-02-22 苏州富士莱医药股份有限公司 制备r-硫辛酸胆碱酯卤化物的方法
CN107089967A (zh) * 2017-05-12 2017-08-25 苏州富士莱医药股份有限公司 一种r‑硫辛酸胆碱酯卤化物的制备方法
EP3749303A4 (en) * 2018-02-05 2022-01-26 Cellixbio Private Limited COMBINATION OF AN ANTIMUSCARINE OR ANTICCHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF
US11158871B2 (en) 2018-07-18 2021-10-26 GM Global Technology Operations LLC Fuel cell assembly and a vehicle that utilizes the fuel cell assembly
US11985964B2 (en) 2018-08-03 2024-05-21 Kevin F Lohmeier Fishing rod holder
CN108822077A (zh) 2018-08-07 2018-11-16 苏州富士莱医药股份有限公司 一种r-硫辛酸胆碱酯卤化物的精制方法
CN108586429A (zh) 2018-08-07 2018-09-28 苏州富士莱医药股份有限公司 R-硫辛酸胆碱酯卤化物的纯化精制方法

Also Published As

Publication number Publication date
CN113387923A (zh) 2021-09-14
EP4118079A1 (en) 2023-01-18
US11590158B2 (en) 2023-02-28
ECSP22069611A (es) 2022-10-31
DOP2022000179A (es) 2022-09-30
CR20220449A (es) 2022-10-12
TW202140435A (zh) 2021-11-01
WO2021181361A1 (en) 2021-09-16
US20210283171A1 (en) 2021-09-16
CO2022012653A2 (es) 2022-09-09
PE20230242A1 (es) 2023-02-07
JP2022058376A (ja) 2022-04-12
CA3175077A1 (en) 2021-09-16
TWI768760B (zh) 2022-06-21
IL295378A (en) 2022-10-01
US20210393671A1 (en) 2021-12-23
MX2022011206A (es) 2022-09-19
US11135239B1 (en) 2021-10-05
JOP20220211A1 (ar) 2022-09-08
BR112022018043A2 (pt) 2022-10-18
JP2021147392A (ja) 2021-09-27
JP7041298B2 (ja) 2022-03-23
AU2021235563A1 (en) 2022-09-22
CN115279745A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
KR102357471B1 (ko) 중수소 농축 N-아세틸시스테인 아미드(D-NACA) 및 (2R,2R')-3,3'-디설판디일 비스(2-아세트아미도프로판아미드)(Di-NACA)의 제조방법 및 산화 스트레스를 포함하는 질환을 치료하기 위한 D-NACA 및 Di-NACA의 사용방법
ES2652187T3 (es) Fenilacetato de l-ornitina y métodos para elaborar el mismo
ES2972099T3 (es) Formulación oftálmica
EA025414B1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
CN112933075A (zh) 局部给药的葛根相关药物组合物
JP2016094471A (ja) 結晶形態ｉｉの７−［３，５−ジヒドロキシ−２−（３−ヒドロキシ−５−フェニル−ペント−１−エニル）−シクロペンチル］−ｎ−エチル−ヘプト−５−エナミド（ビマトプロスト）、その調製方法、およびその使用方法
US20150265549A1 (en) Stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone
TWI768760B (zh) 硫辛酸膽鹼酯鹽的藥物組成物及使用其之治療方法
JP7250685B2 (ja) ピリジルアミノ酢酸化合物を含有する医薬
CN112972683A (zh) 局部给药的葛林佐胺等药物组合物
JPH0427976B2 (cg-RX-API-DMAC10.html)
US12492192B2 (en) Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
JP3094233B2 (ja) （ｓ）−チモロール半水和物を含有する局所眼科治療用組成物及びその製造方法
ES2988906T3 (es) Formas cristalinas de solvatos de derivados del triptófano, composiciones que los comprenden y usos de los mismos
JP2021147392A5 (cg-RX-API-DMAC10.html)
US5496820A (en) Ophthalmic use of S-timolol hemihydrate
JP7788768B2 (ja) Ｍ－コリン受容体アゴニスト化合物及びその製造方法並びに使用
US20250101009A1 (en) Compounds, Compositions and Methods for Treatment of Age-Related Ocular Disorders
WO2013114397A2 (en) Pharmaceutically acceptable salt of brinzolamide and composition thereof
JP2013082696A (ja) フラビンアデニンジヌクレオチドまたはその塩を有効成分として含有する角膜上皮細胞死の抑制剤
JP2025538598A (ja) ピリジンフェニル化合物を含有する眼科用製剤、その調製方法および使用
HK40089977A (en) Crystalline forms of solvates of tryptophan derivatives, compositions comprising them and uses thereof
WO2024050516A2 (en) Varenicline related compounds and methods for treating diseases and conditions including tobacco use disorder
EP4583840A1 (en) Aqueous pharmaceutical compositions comprising benzyl atropine and uses thereof
TR2022007363A2 (tr) Nonsteroi̇dal anti̇enflamatuvar etken madde i̇çeren bi̇leşi̇m

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20220923

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220923

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240904

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241118

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D